Lecanemab in Early Alzheimer's Disease

To the Editor: In the phase 3 Clarity AD trial by van Dyck et al. (Jan. 5 issue),(1) the primary end point was the change from baseline to 18 months in the score on the Clinical Dementia Rating-Sum of Boxes (CDR-SB; scores range from 0 to 18, with higher scores indicating greater impairment). The minimal clinically relevant change in the CDR-SB score has been estimated to be 1 to 2 points.(2) At 18 months, the CDR-SB score had increased from baseline by 1.21 points with lecanemab and by 1.66 points with placebo, for a significant between-group difference of -0.45 points.(1) . . .

Automated summary

This article discusses the results of van Dyck et al.'s study in the Clarity AD trial. The primary endpoint of the study was the change in Clinical Dementia Rating-Sum of Boxes (CDR-SB) score from baseline to 18 months. The results showed a significant difference of -0.45 points in the CDR-SB score between the lecanemab and placebo groups, indicating clinical significance.